Another Phase 1 clinical trial of TG4050 is enrolling patients with newly diagnosed, locoregionally advanced, HPV negative, squamous cell carcinoma of the head and neck (SCCHN) that have received an adjuvant (first-line) therapy after surgery. This multi-center, open label, randomized two arms ...
These data pave the way for further development and synergistic immunotherapeutic combinations.Clinical trial information: NCT04183166.Jean-Pierre DelordDepartment of Oncology, Institut Claudius Regaud,IUCT-Oncopole, Toulouse, France;Matthew Stephen Block...